2023 World Conference on Lung Cancer (Posters)-EP07.02. Prospective Study of Hypofractionated Proton Therapy for Inoperable Early Stage Non-small Cell Lung Cancer

EP07.02. Prospective Study of Hypofractionated Proton Therapy for Inoperable Early Stage Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A prospective study conducted at the Samsung Medical Center in Korea evaluated the use of hypofractionated proton therapy for inoperable early stage non-small cell lung cancer (NSCLC) patients. The study aimed to assess the local control rate, overall survival, quality of life, and toxicity associated with this treatment modality.<br /><br />The study included 27 adult patients with NSCLC who were deemed unfit for surgical resection or stereotactic body radiotherapy (SBRT). The treatment involved hypofractionated proton therapy prescribed with 64 Cobalt Gray Equivalent in 8 fractions.<br /><br />The results showed a 2-year local control rate of 73.5%, with higher rates observed in T1 tumors (85.7%) compared to T2-3 tumors (61.4%). Factors associated with worse local control included larger clinical target volume and a history of heavy smoking.<br /><br />The 2-year overall survival rate was 76.5%. Grade 3 toxicities were observed in two patients, including radiation pneumonitis in a patient with underlying idiopathic pulmonary fibrosis and dermatitis in another patient. The overall quality of life did not change significantly, but there was an increase in dyspnea scores at 4 months after treatment.<br /><br />The study concluded that hypofractionated proton therapy is a safe treatment option for inoperable NSCLC patients, particularly those with smaller tumor volumes. However, further improvement is needed to achieve better local control in larger tumors.<br /><br />This study provides valuable insights into the use of hypofractionated proton therapy for inoperable early stage NSCLC patients, highlighting its potential benefits in terms of local control and overall survival.

Asset Subtitle

Kyungmi Yang

Meta Tag

Speaker Kyungmi Yang

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

prospective study

hypofractionated proton therapy

NSCLC

local control rate

overall survival

toxicity

surgical resection

clinical target volume

radiation pneumonitis

tumor volumes